catalpol has been researched along with Ischemic Stroke in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Chen, YJ; Feng, S; Jiang, BX; Ran, HF; Ren, HJ; Wang, HJ; Xu, XG; Xu, XY; Xue, Q; Yin, Y; Yu, SQ; Zhang, JF | 1 |
| Sun, S; Tian, Z; Wan, D; Wang, J; Xu, Y; Yu, N; Zhang, M; Zhu, H | 1 |
2 other study(ies) available for catalpol and Ischemic Stroke
| Article | Year |
|---|---|
Catalpol improves impaired neurovascular unit in ischemic stroke rats via enhancing VEGF-PI3K/AKT and VEGF-MEK1/2/ERK1/2 signaling.
Topics: Animals; Iridoid Glucosides; Ischemic Stroke; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Vascular Endothelial Growth Factor A | 2022 |
Catalpol Alleviates Ischemic Stroke Through Promoting Angiogenesis and Facilitating Proliferation and Differentiation of Neural Stem Cells via the VEGF-A/KDR Pathway.
Topics: Animals; Cell Differentiation; Cell Proliferation; Endothelial Cells; Ischemic Stroke; Neural Stem Cells; Oxygen; Rats; RNA, Small Interfering; Stroke; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2023 |